VARDENAFIL HCL 5 MG TABLET

What it is

VARDENAFIL HCL 5 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “vardenafil” and “vardenafil hydrochloride”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as “tablet, film coated” and “tablet” and its route as oral.

FDA lists 4 labelers (the companies named on the label) for its NDCs, among them Teva Pharmaceuticals USA, Inc., Lannett Company, Inc. and Macleods Pharmaceuticals Limited.

FDA’s Established Pharmacologic Class for it is Phosphodiesterase 5 Inhibitor.

The NADAC file of 2026-10-14 prices it under 4 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $212.99 for 30 tablets (30 × $7.0998 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-03-18. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 4, carried forward from the previous file.

The NADAC of all 4 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-03-18. The file is new; the price is not.

What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices

All 4 NDCs

• 00093-7653-56 · Teva Pharmaceuticals USA, Inc. · $7.0998 per EA · eff. 2026-03-18 filed carried forward
• 00527-2801-32 · Lannett Company, Inc. · $7.0998 per EA · eff. 2026-03-18 filed carried forward
• 33342-0152-07 · Macleods Pharmaceuticals Limited · $7.0998 per EA · eff. 2026-03-18 filed carried forward
• 70710-1069-03 · Zydus Pharmaceuticals USA Inc. · $7.0998 per EA · eff. 2026-03-18 filed carried forward

Other strengths, forms and brands

3 other products in the NADAC file share an FDA nonproprietary name with VARDENAFIL HCL 5 MG TABLET.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-03-18, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 4 NDCs’ NADAC prices is $7.0998 per EA filed.

Of the 17 other products in FDA’s Phosphodiesterase 5 Inhibitor class priced per EA, 6 have a higher middle NADAC price and 11 a lower one. The one in the middle is TADALAFIL 20 MG TABLET, at $0.16709 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-03-18, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $526.56 for 30 tablets, at an average of $17.55195 per EA in 2024 (2024-01-01 to 2024-12-31) for “Vardenafil HCl”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 4,738 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.